EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Advances in RARα fusion genes in acute promyelocytic leukemia

Ao Zhang, Shaowei Qiu

Experimental Hematology · 2025

DOI: 10.1016/j.exphem.2025.104822 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Experimental Hematology, 2025. Verfasst von Ao Zhang und 1 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute …. Hauptthemen laut MEDLINE: Leukemia, Promyelocytic, Acute, Oncogene Proteins, Fusion, Retinoic Acid Receptor alpha. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 114 Literaturangaben. Gefördert von: CAMS Innovation Fund for Medical Sciences, Tianjin Municipal Science and Technology Committee, Tianjin Municipal Science and Technology Bureau.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Retinoic acid receptor α (RARα) is a ligand-dependent transcription factor that dimerizes with retinoid X receptor α (RXRα) to activate target gene promoters, playing a critical role in normal hematopoiesis and granulocyte differentiation. The translocation of chromosomes 15 and 17 generates the promyelocytic leukemia-retinoic acid receptor α (PML-RARα) fusion gene, the master driver of acute promyelocytic leukemia (APL). The PML-RARα oncoprotein exerts two major effects: transcriptional repression and disruption of promyelocytic leukemia (PML) function. The introduction of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) has significantly improved the complete remission rate in APL, making it a highly treatable disease. However, resistance to ATRA/ATO and the emergence of variant fusion genes remain significant challenges to improving APL prognosis. This review provides an overview of the physiological role of retinoid nuclear receptor signaling in hematopoiesis, the pathological mechanisms of PML-RARα in APL, the pharmacologic effects of ATRA/ATO, and the variant translocations identified in APL. We aimed to provide innovative research perspectives and insights that may be applicable to other hematopoietic malignancies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Promyelocytic, AcuteOncogene Proteins, FusionRetinoic Acid Receptor alphaHumansArsenic TrioxideTretinoinAnimalsAntineoplastic AgentsTranslocation, GeneticSignal Transduction

Substanzen

Oncogene Proteins, FusionRetinoic Acid Receptor alphaArsenic TrioxideTretinoinpromyelocytic leukemia-retinoic acid receptor alpha fusion oncoproteinRARA protein, humanAntineoplastic Agents

Autor:innen und Institutionen

  • State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc…

Förderung

  • CAMS Innovation Fund for Medical Sciences
  • Tianjin Municipal Science and Technology Committee
  • Tianjin Municipal Science and Technology Bureau

Zitieren

APA

Zhang, A., & Qiu, S. (2025). Advances in RARα fusion genes in acute promyelocytic leukemia. Experimental Hematology. https://doi.org/10.1016/j.exphem.2025.104822

Vancouver

Zhang A, Qiu S. Advances in RARα fusion genes in acute promyelocytic leukemia. Experimental Hematology. 2025. doi:10.1016/j.exphem.2025.104822

BibTeX
@article{Zhang2025,
  author = {Zhang, Ao and Qiu, Shaowei},
  title = {Advances in RARα fusion genes in acute promyelocytic leukemia},
  journal = {Experimental Hematology},
  year = {2025},
  doi = {10.1016/j.exphem.2025.104822}
}
Kostenlos starten →